Recent advances in the management of hepatocellular carcinoma

Liver cancer remains a challenge of global health, being the 4th leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and is usually precipitated by chronic viral infections (hepatitis B and C), non-alcoholic steatohepatitis, heavy...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clinical and Molecular Hepatology Ročník 30; číslo 1; s. 1 - 15
Hlavní autoři: Sankar, Kamya, Gong, Jun, Osipov, Arsen, Miles, Steven A., Kosari, Kambiz, Nissen, Nicholas N., Hendifar, Andrew E., Koltsova, Ekaterina K., Yang, Ju Dong
Médium: Journal Article
Jazyk:angličtina
Vydáno: Korea (South) The Korean Association for the Study of the Liver 01.01.2024
Korean Association for the Study of the Liver
대한간학회
Témata:
Ablation
Cancer therapies
Carcinoma
Carcinoma, Hepatocellular - etiology
Carcinoma, Hepatocellular - therapy
Diseases of the digestive system. Gastroenterology
FDA approval
Hepatitis B
Hepatitis B - complications
Hepatitis C
Hepatocellular
Hepatocellular carcinoma
Humans
Immunotherapy
Kinases
Liver cancer
Liver Cirrhosis
Liver Cirrhosis - complications
Liver Neoplasms
Liver Neoplasms - complications
Liver transplants
Medical prognosis
RC799-869
Response rates
Review
Tyrosine protein kinase inhibitors
내과학
United States > US
Liver cancer
Hepatocellular carcinoma
Tyrosine protein kinase inhibitors
Immunotherapy
ISSN:2287-2728, 2287-285X, 2287-285X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Liver cancer remains a challenge of global health, being the 4th leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and is usually precipitated by chronic viral infections (hepatitis B and C), non-alcoholic steatohepatitis, heavy alcohol use, and other factors which may lead to chronic inflammation and cirrhosis of the liver. There have been significant advances in the systemic treatment options for HCC over the past decades, with several approvals of both immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with preserved liver function. These advances have led to improvement in survival outcomes, with expected survival of greater than 18 months, in those with sensitive tumors, adequate liver function, and those functionally fit to receive sequential therapies. Several ongoing and promising trials are now evaluating combinational strategies with novel systemic agents and combinations of systemic therapy with locoregional therapy. In view of these trials, further advances in the treatment of HCC are foreseen in the near future.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Editor: Naoshi Nishida, Kindai University, Japan
ISSN:2287-2728
2287-285X
2287-285X
DOI:10.3350/cmh.2023.0125